JPWO2020056145A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056145A5 JPWO2020056145A5 JP2021513989A JP2021513989A JPWO2020056145A5 JP WO2020056145 A5 JPWO2020056145 A5 JP WO2020056145A5 JP 2021513989 A JP2021513989 A JP 2021513989A JP 2021513989 A JP2021513989 A JP 2021513989A JP WO2020056145 A5 JPWO2020056145 A5 JP WO2020056145A5
- Authority
- JP
- Japan
- Prior art keywords
- lmdv
- antigen
- binding portion
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 41
- 230000036436 anti-hiv Effects 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 5
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102220056037 rs797044515 Human genes 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000003472 neutralizing effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical class N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102220200274 rs1057521155 Human genes 0.000 claims 2
- 102220014491 rs141658242 Human genes 0.000 claims 2
- 102200027495 rs33946261 Human genes 0.000 claims 2
- 102200054149 rs397515527 Human genes 0.000 claims 2
- 102200094071 rs72466451 Human genes 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731356P | 2018-09-14 | 2018-09-14 | |
| US62/731,356 | 2018-09-14 | ||
| PCT/US2019/050823 WO2020056145A1 (en) | 2018-09-14 | 2019-09-12 | Anti-hiv antibody 10-1074 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500042A JP2022500042A (ja) | 2022-01-04 |
| JPWO2020056145A5 true JPWO2020056145A5 (https=) | 2022-09-16 |
| JP2022500042A5 JP2022500042A5 (https=) | 2022-09-16 |
Family
ID=69778483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513989A Pending JP2022500042A (ja) | 2018-09-14 | 2019-09-12 | 抗ｈｉｖ抗体１０−１０７４バリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12441782B2 (https=) |
| EP (1) | EP3849612A4 (https=) |
| JP (1) | JP2022500042A (https=) |
| KR (1) | KR102938690B1 (https=) |
| CN (2) | CN121021680A (https=) |
| AU (1) | AU2019338454A1 (https=) |
| CA (1) | CA3112486A1 (https=) |
| WO (1) | WO2020056145A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| US12195524B2 (en) | 2020-08-25 | 2025-01-14 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| WO2023154761A2 (en) * | 2022-02-08 | 2023-08-17 | The Wistar Institute Of Anatomy And Biology | Modified primary immune cells for induction or enhancement of immunotherapy |
| KR20250051732A (ko) * | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US81A (en) | 1836-11-15 | Erawijjg | ||
| US6593A (en) | 1849-07-17 | Cutting | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| JPH10511085A (ja) | 1994-12-02 | 1998-10-27 | カイロン コーポレイション | 二重特異性抗体を用いる免疫応答を促進する方法 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| CA3249351A1 (en) * | 2010-08-31 | 2025-07-03 | Theraclone Sciences, Inc. | Neutralizing antibodies against human immunodeficiency viruses (HIV) |
| EA032929B1 (ru) * | 2011-05-17 | 2019-08-30 | Дзе Рокфеллер Юниверсити | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения |
| WO2013192589A1 (en) * | 2012-06-21 | 2013-12-27 | California Institute Of Technology | Antibodies targeting hiv escape mutants |
| LT2908912T (lt) * | 2012-10-18 | 2020-09-25 | The Rockefeller University | Plačiai neutralizuojantys anti-živ antikūnai |
| US10676521B2 (en) * | 2014-07-21 | 2020-06-09 | The Rockefeller University | Combination of broadly neutralizing HIV antibodies and viral inducers |
| MX2019007738A (es) * | 2016-12-27 | 2019-09-05 | Univ Rockefeller | Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos. |
| WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
-
2019
- 2019-09-12 WO PCT/US2019/050823 patent/WO2020056145A1/en not_active Ceased
- 2019-09-12 JP JP2021513989A patent/JP2022500042A/ja active Pending
- 2019-09-12 US US17/275,310 patent/US12441782B2/en active Active
- 2019-09-12 CN CN202511190725.6A patent/CN121021680A/zh active Pending
- 2019-09-12 EP EP19859927.6A patent/EP3849612A4/en active Pending
- 2019-09-12 CA CA3112486A patent/CA3112486A1/en active Pending
- 2019-09-12 KR KR1020217011145A patent/KR102938690B1/ko active Active
- 2019-09-12 AU AU2019338454A patent/AU2019338454A1/en active Pending
- 2019-09-12 CN CN201980074145.7A patent/CN113271974B/zh active Active
-
2025
- 2025-08-13 US US19/298,749 patent/US20260049122A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500042A5 (https=) | ||
| US20150174235A1 (en) | Vaccine | |
| US20180140694A1 (en) | Dosage regimen for hiv vaccine | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| WO2016005508A1 (en) | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) | |
| JPWO2020056145A5 (https=) | ||
| JPWO2019177888A5 (https=) | ||
| ES2360334T3 (es) | Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus. | |
| Stein et al. | Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual | |
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| EA013008B1 (ru) | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с | |
| WO2015086738A2 (en) | Hiv vaccine | |
| JP2022035920A5 (https=) | ||
| US10449245B2 (en) | Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent | |
| JPWO2022018729A5 (https=) | ||
| US7015016B2 (en) | Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's | |
| JP2004002455A (ja) | レトロウイルス感染の阻害 | |
| JP2014510126A5 (ja) | Ｉｆｎアルファ関連疾病の処置方法 | |
| US10143737B2 (en) | Method for the vaccination against HIV | |
| JP4330948B2 (ja) | ケモカインレセプターｃｃｒ−５に対する抗体酵素、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらを利用した抗ｈｉｖ薬剤 | |
| RU2024111536A (ru) | Лекарственное средство для лечения жировой инфильтрации печени и неалкогольного стеатогепатита | |
| RU2025114747A (ru) | Антигенсвязывающие белки область техники, к которой относится изобретение | |
| JP2019524089A5 (https=) | ||
| JPWO2020117590A5 (https=) | ||
| RU2023117116A (ru) | Способ лечения синдрома шегрена с использованием слитого белка taci-fc |